One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies
Breaking the link: IL-6 targeting to uncouple toxicity and efficacy in patients treated with immune checkpoint blockade
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)☆
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study☆
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer☆
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Subcutaneous versus intravenous nivolumab for renal cell carcinoma☆
Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies☆
Artificial intelligence-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu
Letter to the Editor regarding ‘A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse’ by JY Blay et al.
Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse
Optimising treatment strategies in metastatic colorectal cancer: insights from CAIRO4
Reply to Letter to the Editor “Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4� by Güzel et al.
